Skip to main content
Videos

The Role of Antipsychotic TDM in Clinical Decision Making: The Example of Clozapine

By July 1, 2023January 19th, 2024No Comments

The Role of Antipsychotic TDM in Clinical Decision Making: The Example of Clozapine

Recorded at the April 2022 Annual Meeting of the College of Psychiatric and Neurologic Pharmacists (CPNP)

More InfoView More Webinars

Description:

Readily available therapeutic drug monitoring (TDM) of antipsychotic blood levels can provide evidence-based and personalized psychopharmacologic treatment. For medications such as clozapine, patients and healthcare providers have many situations where TDM is highly relevant in making day-to-day clinical decisions, including differentiating poor adherence with ultrarapid metabolism, and optimizing levels in inadequate responders. During this session, the faculty will discuss the unique place of clozapine for treatment resistant schizophrenia, and the role of TDM in clozapine dosing during titration, and for monitoring ongoing adherence.

Presenting Faculty:

Jonathan Meyer, MD

  • Clinical Professor of Psychiatry, University of California, San Diego
  • Psychopharmacology Consultant, California Department of State Hospitals

Rob Cotes, MD, DFAPA

  • Director, Clinical and Research Program for Psychosis, Grady Health Systems
  • Associate Professor, Emory School of Medicine, Department of Psychiatry and Behavioral Sciences

Deanna Kelly, PhamD, BCPP

  • MPower Professor of Psychiatry, University of Maryland Strategic Partnership: MPowering the State
  • Acting Director and Chief, Treatment Research Program (TRP) Maryland Psychiatric Research Center (MPRC) University of Maryland School of Medicine

Megan Ehret, PharmD, MS, BCPP

  • Professor, Department of Pharmacy Practice and Science, University of Maryland School of Medicine

Additional Resources:

For additional handouts, questions, or inquiries, please contact hello@saladax.com or enter your email below!


Leave a Reply

Close Menu